for people ages 18-79 (full criteria)
at UC Davis UCLA
study started
estimated completion



This is an open-label study to evaluate the safety of continued therapy with oral treprostinil in subjects who have completed Study TDE-HF-301. This study will provide long-term, open-label data regarding the effect of continued long-term oral treprostinil therapy for the treatment of pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF). Subject visits will occur at Baseline, Weeks 6, 12, 18, 24, and every 12 weeks thereafter until either oral treprostinil becomes commercially available to treat PH associated with HFpEF or the study is discontinued by the Sponsor.

Official Title

An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301


Pulmonary Hypertension Associated With HFpEF Pulmonary Hypertension HFpEF 6-Minute Walk Test Oral Treprostinil Hypertension, Pulmonary Hypertension Heart Failure Treprostinil


You can join if…

Open to people ages 18-79

  • The subject participated in Study TDE-HF-301, remained on study drug, was compliant with study procedures and assessments during Study TDE-HF-301, and completed through Week 24 of that study.

You CAN'T join if...

  • The subject is pregnant or lactating.
  • The subject was prematurely discontinued from Study TDE-HF-301 for any reason.
  • The subject developed a concurrent illness or condition during Study TDE HF 301, which, in the opinion of the Investigator, would represent a risk to the subject's overall health if they enrolled in this study.


  • University of California Los Angeles Pulmonary Division
    Los Angeles California 90095 United States
  • University of California - Davis Medical Center
    Sacramento California 95817 United States
  • Cedars-Sinai Medical Center
    Los Angeles California 90211 United States


in progress, not accepting new patients
Start Date
Completion Date
United Therapeutics
Phase 3
Study Type
Last Updated